TKI-based regimens were associated with higher rates of disease control in metastatic translocation renal cell carcinoma.
|Videos|August 23, 2017
Dr. Gupta on PD-L1 as a Biomarker in Kidney Cancer
Author(s)Shilpa Gupta, MD, Cleveland Clinic
Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses PD-L1 as a biomarker in kidney cancer.
Advertisement
Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses PD-L1 as a biomarker in kidney cancer.
The biomarker question is something that needs to be tackled, says Gupta. Additionally, in kidney cancer, it is not known whether PD-L1 is a predictive biomarker.
Advertisement
Related to this article
David R. Gandara, MD, discusses why PD-L1 scoring in NSCLC undercounts immunotherapy benefit and where TMB and plasma proteomics fit alongside it.
Edgardo S. Santos Castillero, MD, discusses MAVERICK, B7-H3 ADC data, and tarlatamab sequencing in SCLC, plus molecular testing in a value-based practice.
Advertisement
Advertisement